Pathalys Pharma
PrivateLast Round
Series B
Aug 20, 2024
Est. Valuation
$295M
Total Funding Raised
$255M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Pathalys Pharma operates in Healthcare & Life Sciences and is based in Raleigh, North Carolina. Its latest recorded funding round was a Series B round in August 2024.
Pathalys Pharma is a biopharmaceutical company that develops advanced therapeutics to address unmet needs in the management of end-stage kidney disease.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Pathalys Pharma Comparables
Compare Pathalys Pharma with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Kissei Pharmaceutical | 79% | |
| Amgen | 77% | |
| Eisai | 76% |
For institutional investors. Book with your work email.
Pathalys Pharma Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Aug 20, 2024 | ||||
| Early Funding | Jan 18, 2023 | ||||
| Seed | Mar 1, 2022 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Pathalys Pharma Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Japan Post Investment Corporation | Series B |
| TCG Crossover | Series B |
| KB Investment | Series B |
| KB Investment | Series B |
| OrbiMed | Early Funding |
| Japan Post Bank Asset Management Co., Ltd. | Series B |
| The Carlyle Group | Early Funding |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 11, 2026
Monthly visitors increased 34% MoM.
- Aug 21, 2026
Monthly visitors increased 66% MoM.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- attends_eventOct 5, 2026
Pathalys Pharma, Inc. delivers data from its Phase 3 program for upacicalcet as a featured late-breaking oral presentation at ASN Kidney Week 2026 in Colorado in Oct '26.
For institutional investors. Book with your work email.
Pathalys Pharma Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Pathalys Pharma's valuation, stock price, and market status.
Is Pathalys Pharma a public or private company?
Pathalys Pharma is a private company.
What is the current stock price of Pathalys Pharma?
Pathalys Pharma is a private company, so its shares have no public market price. Caplight tracks Pathalys Pharma's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Pathalys Pharma worth (valuation)?
Pathalys Pharma's valuation is estimated at $295.0M based on funding round data.
Can I buy Pathalys Pharma stock?
Pathalys Pharma shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Pathalys Pharma's last funding round?
Pathalys Pharma's most recent funding round was Series B on August 20, 2024.
Who are the main investors in Pathalys Pharma?
Key investors in Pathalys Pharma include TCG Crossover, Abingworth.
Will Pathalys Pharma IPO soon?
No public IPO plans have been announced for Pathalys Pharma.
How can I track Pathalys Pharma secondary market activity?
Caplight tracks bids, offers, and trades in Pathalys Pharma's shares on secondary markets.